GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,162 | -7,597 | -20,884 | -58,013 | -28,296 |
| Depreciation Amortization | N/A | N/A | N/A | N/A | 317 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 7,077 | -838 |
| Other Working Capital | 828 | 1,937 | -1,894 | 8,660 | 17,065 |
| Other Operating Activity | -570 | -3,192 | 7,561 | 26,670 | 4,490 |
| Operating Cash Flow | $-12,904 | $-8,852 | $-15,217 | $-15,606 | $-7,262 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 12,893 | -2,009 | N/A | N/A | N/A |
| Purchase Of Investment | N/A | N/A | 12,145 | -23,040 | N/A |
| Investing Cash Flow | $12,893 | $-2,009 | $12,145 | $-23,040 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 1,205 | 12,531 |
| Common Stock Issued | 2,976 | 6,268 | N/A | 41,112 | 0 |
| Other Financing Activity | 0 | 0 | -224 | 0 | 0 |
| Financing Cash Flow | $2,976 | $6,268 | $-224 | $42,317 | $12,531 |
| Beginning Cash Position | 1,079 | 5,672 | 8,968 | 5,297 | 28 |
| End Cash Position | 4,044 | 1,079 | 5,672 | 8,968 | 5,297 |
| Net Cash Flow | $2,965 | $-4,593 | $-3,296 | $3,671 | $5,269 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,904 | -8,852 | -15,217 | -15,606 | -7,262 |
| Free Cash Flow | -12,904 | -8,852 | -15,217 | -15,606 | -7,262 |